AR and posterior cortical atrophy: The majority of PCa patients expresses androgen receptor (AR) at high levels and responds to androgen deprivation therapies (ADT, surgical or medical castration) (2–4), but patients usually relapse and evolves into castration resistant prostate cancer (CRPC) within 2–3 years, finally leading to death (5).